menu
    • menu
    [{"orgOrder":0,"company":"Alebund Pharmaceuticals","sponsor":"3H Health Investment","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"AP-302","moa":"MASP-2","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Alebund Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alebund Pharmaceuticals \/ 3H Health Investment","highestDevelopmentStatusID":"5","companyTruncated":"Alebund Pharmaceuticals \/ 3H Health Investment"},{"orgOrder":0,"company":"Alebund Pharmaceuticals","sponsor":"Quan Capital","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"CHINA","productType":"Peptide","year":"2021","type":"Series B Financing","leadProduct":"Solnatide","moa":"Na channel","graph1":"Nephrology","graph2":"Phase III","graph3":"Alebund Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alebund Pharmaceuticals \/ Quan Capital","highestDevelopmentStatusID":"10","companyTruncated":"Alebund Pharmaceuticals \/ Quan Capital"},{"orgOrder":0,"company":"Alebund Pharmaceuticals","sponsor":"Yangzhou Guojin Investment Group","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"CHINA","productType":"Peptide","year":"2025","type":"Series C Financing","leadProduct":"Solnatide","moa":"Na channel","graph1":"Nephrology","graph2":"Phase III","graph3":"Alebund Pharmaceuticals","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0.080000000000000002,"dosageForm":"Oral Capsule","sponsorNew":"Alebund Pharmaceuticals \/ Yangzhou Guojin Investment Group","highestDevelopmentStatusID":"10","companyTruncated":"Alebund Pharmaceuticals \/ Yangzhou Guojin Investment Group"},{"orgOrder":0,"company":"Alebund Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AP303","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Alebund Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alebund Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alebund Pharmaceuticals \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Alebund Pharmaceuticals

    Menu

    Alebund Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Alebund Pharmaceuticals

                            China arrow
                            AACR Annual meeting
                            Not Confirmed

                            Alebund Pharmaceuticals

                            China arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Solnatide

                            Therapeutic Area : Nephrology

                            Study Phase : Phase III

                            Sponsor : Yangzhou Guojin Investment Group

                            Deal Size : $75.6 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            Alebund Pharmaceutical announced the 1st closing of RMB 550 million in Series C financing

                            Details : The fund will support accelerating new drug application (NDA) in China for the best-in-class iron-based phosphate binder AP301 for treating Hyperphosphatemia.

                            Product Name : AP301

                            Product Type : Peptide

                            Upfront Cash : Undisclosed

                            January 07, 2025

                            Lead Product(s) : Solnatide

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase III

                            Sponsor : Yangzhou Guojin Investment Group

                            Deal Size : $75.6 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Alebund Pharmaceuticals

                            China arrow
                            AACR Annual meeting
                            Not Confirmed

                            Alebund Pharmaceuticals

                            China arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AP303

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Alebund's AP303 Receives FDA Orphan Drug Designation for Polycystic Kidney Disease

                            Details : AP303 is a pan-inhibitor of sodium-dependent phosphate transporters. It is being evaluated for the treatment of autosomal dominant polycystic kidney disease.

                            Product Name : AP-303

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 29, 2024

                            Lead Product(s) : AP303

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Alebund Pharmaceuticals

                            China arrow
                            AACR Annual meeting
                            Not Confirmed

                            Alebund Pharmaceuticals

                            China arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AP-302

                            Therapeutic Area : Nephrology

                            Study Phase : IND Enabling

                            Sponsor : 3H Health Investment

                            Deal Size : $54.5 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Alebund Pharmaceuticals Raises $54.5 Million in Series B+ Financing Round to Fuel Development of Renal Disease...

                            Details : Proceeds raised will help accelerate the development of AP-302 and Alebund’s other clinical programs, the construction of the manufacturing site, the research of pre-clinical assets, and the expansion of Company’s talent pool.

                            Product Name : AP-302

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            September 14, 2021

                            Lead Product(s) : AP-302

                            Therapeutic Area : Nephrology

                            Highest Development Status : IND Enabling

                            Sponsor : 3H Health Investment

                            Deal Size : $54.5 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Alebund Pharmaceuticals

                            China arrow
                            AACR Annual meeting
                            Not Confirmed

                            Alebund Pharmaceuticals

                            China arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Solnatide

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Sponsor : Quan Capital

                            Deal Size : $60.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Alebund Pharmaceuticals Raises $60 million in Series B Financing Round

                            Details : Alebund Pharmaceuticals lead product, AP-301, is a best-in-class potential in the treatment of hyperphosphatemia.

                            Product Name : AP-301

                            Product Type : Peptide

                            Upfront Cash : Undisclosed

                            September 05, 2021

                            Lead Product(s) : Solnatide

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Sponsor : Quan Capital

                            Deal Size : $60.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth